Nonalcoholic steatohepatitis (NASH) is a progressive liver disease characterized by fat accumulation, inflammation, and fibrosis. If left untreated, it can progress to cirrhosis and liver failure. As a severe form of nonalcoholic fatty liver disease (NAFLD), NASH is strongly associated with metabolic dysfunction, obesity, and insulin resistance. The increasing NASH prevalence has transformed it into a significant global health challenge, driving the need for innovative treatments.
Why is NASH Widespread?
The rapid rise in NASH prevalence is primarily linked to the global increase in obesity, type 2 diabetes, and sedentary lifestyles. Genetic factors and unhealthy diets further contribute to its widespread nature. Once considered rare, NASH now affects millions, emphasizing the urgent need for treatment breakthroughs.
Advancements in NASH Treatment
Currently, there are no FDA-approved drugs for NASH. However, ongoing research is exploring promising therapies targeting fibrosis, inflammation, and metabolic pathways. Some of the leading drug classes include:
- FXR Agonists – Regulate bile acid metabolism to reduce liver fat.
- GLP-1 Receptor Agonists – Enhance insulin sensitivity and support weight loss.
- PPAR Agonists – Help in lipid metabolism and inflammation reduction.
- Thyroid Hormone Receptor-Beta Agonists – Target liver fat accumulation.
The Future of NASH Treatment
With increasing research and investment in pharmaceuticals, the landscape of NASH management is evolving. As NASH prevalence rises, researchers remain committed to tackling NASH effectively, offering new hope for improved patient care.
Latest Reports Offered By Delveinsight
Attention Deficit Hyperactivity Disorder Market | Lactose Intolerance Market | Urea Cycle Disorders Market | Overactive Bladder Syndrome Market | Surgical Energy Instruments Market | Pipeline Assessment Services | Penile Cancer Market | Total Knee Arthroplasty Market | Indwelling Catheters Market
Contact Information
Kanishk
[email protected]